Mutant mice lacking cyclin D1 are entirely resistant to breast tumours induced by neu and ras, genes implicated in most human breast cancers, but are susceptible to those tumours caused by the other oncogenes c-myc and Wnt-1. So Piotr Sicinsky and colleagues of the Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, report in this week’s Nature (Vol. 411, No. 6841, 28 Jun 2001).
Although it remains to be seen whether these findings translate to humans, the results suggest that those human breast cancers caused by neu and ras could be treated with anti-cyclin D1 therapy. Cyclin D1 is one of many proteins involved in cell proliferation.
"It might one day be possible to provide tailor-made treatments," say Jiri Bartek and Jiri Lukas of the Institute of Cancer Biology, Danish Cancer Society, Copenhagen, in an accompanying News and Views article. Molecular profiles of breast-cancer patients could be drawn up using DNA chips, or assays.
tel +1 617 632 5005
tel +45 35 25 73 57
(C) Nature press release.
Message posted by: Trevor M. D'Souza
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.
Use the links below to share this article on the social bookmarking site of your choice.
Read more about social bookmarking at Wikipedia - Social Bookmarking
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...